Fortress Biotech (FBIO) Gains from Investment Securities (2015 - 2016)
Fortress Biotech (FBIO) posted quarterly Gains from Investment Securities of $16000.0 for Q3 2016, down 82.02% quarter-over-quarter from $89000.0 in Q1 2016.
Powered by 
Analysis
Fortress Biotech (FBIO) Gains from Investment Securities (2015 - 2016) Analysis & Trends
Fortress Biotech's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $16000.0 for Q3 2016.
- In Q3 2016, Gains from Investment Securities changed N/A year-over-year to $16000.0; the TTM figure through Sep 2016 stood at $543000.0 (changed N/A YoY), while the FY2015 annual figure was $438000.0, changed N/A from the prior year.
- Gains from Investment Securities for Q3 2016 stood at $16000.0, down from $89000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $438000.0 in Q4 2015, with the low at $16000.0 in Q3 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2016 | 16,000.00 |
| Mar 31, 2016 | 89,000.00 |
| Dec 31, 2015 | 438,000.00 |